Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

Daniel Veigel(Comprehensive Cancer Center Vienna), Thomas W. Grunt(Comprehensive Cancer Center Vienna)

International Journal of Cancer

October 10, 2014

10.1002/ijc.29261

Cited by 62

Related Papers

Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells

|International Journal of Cancer|1995|70

Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells

|Oncotarget|2017|57

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells

|Oncotarget|2018|28

Pharmacological Inhibition of Lipid Import and Transport Proteins in Ovarian Cancer

|Cancers|2022|10